Monoclonal Antibody Therapeutics Market - Global Forecast 2025-2030

The monoclonal antibody therapeutics market is undergoing rapid transformation, shaped by advances in technology, evolving regulatory pathways, and new market access strategies. This report equips senior decision-makers with a comprehensive framework to guide investments and strategic planning in this dynamic sector.

Market Snapshot: Monoclonal Antibody Therapeutics Market Overview

The monoclonal antibody therapeutics market grew from USD 169.87 billion in 2024 to USD 189.89 billion in 2025. With a projected CAGR of 11.46%, the market is expected to reach USD 325.76 billion by 2030. Market expansion is propelled by sustained innovation, regulatory evolution, and rising global demand for targeted therapies, particularly in complex and chronic disease sectors. This landscape features ongoing collaboration among pharmaceutical companies, biotechnology firms, and contract manufacturers, resulting in a robust and diverse therapeutic portfolio.

Scope & Segmentation

This report dissects the monoclonal antibody therapeutics market across core segments, technology platforms, and global regions. Key areas of examination include:

Indications: Coverage includes autoimmune disorders (inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis), cardiovascular conditions, infectious diseases (COVID-19, HIV, respiratory syncytial virus), neurological disorders (Alzheimer’s disease, multiple sclerosis), and oncology (hematological malignancies including leukemia, multiple myeloma, non-Hodgkin lymphoma; and solid tumors—breast, colorectal, lung cancers).
Antibody Types: The landscape comprises chimeric, fully human, humanized, and murine monoclonal antibodies, each offering unique clinical and commercial characteristics.
Molecular Targets: Profiling of CD20, EGFR, HER2, and TNF alpha targets, emphasizing differentiated efficacy and safety opportunities.
Production Technologies: Assessment of hybridoma, recombinant DNA, and transgenic animal technologies reveals diverse manufacturing scenarios for yield, efficiency, and scalability.
Route of Administration: Intramuscular, intravenous, and subcutaneous delivery modalities affecting dosing schedules and patient adherence are analyzed.
Distribution Channels: Both offline (hospital, retail, specialty pharmacies) and online pharmacy pathways are examined for their strategic roles in therapy accessibility.
End Users: Clinics, diagnostic laboratories, hospitals, and specialty centers represent the breadth of settings deploying monoclonal antibody therapies.
Therapy Types: Both monotherapy and combination therapy trends underscore personalized, synergistic disease management strategies.
Geographical Coverage: Analysis spans the Americas, Europe, Middle East & Africa, and Asia-Pacific, with country-level granularity for key pharmaceutical and emerging markets.

Industry profiling includes major innovators and collaborative ventures driving competitive shifts.

Key Takeaways

Breakthroughs in antibody engineering—such as bispecific constructs and conjugation technologies—are setting new standards for treatment precision and efficacy.
Global regulatory agencies are adapting approval pathways with expedited reviews and adaptive trials to accelerate time to market without compromising safety.
Manufacturing advances like continuous processing and single-use bioreactor systems are lowering production costs and increasing operational agility.
Regional ecosystems, particularly in the Americas and Asia-Pacific, benefit from robust infrastructure, while value-driven models and biosimilar adoption are shaping dynamics in Europe and emerging markets.
Therapeutic differentiation is increasingly tied to molecular targeting, route of administration, and tailored patient support programs, influencing commercial success and market expansion.
Strategic alliances and portfolio diversification among leading biopharmaceutical enterprises are essential to sustaining innovation pipelines and competitive positioning.

Tariff Impact: Shifting Cost and Supply Chain Dynamics

Upcoming United States tariff adjustments in 2025 are set to disrupt input costs for critical biologic materials and consumables. This shift is expected to drive procurement restructuring, encourage localized production, and prompt contract manufacturing arrangements, especially for emerging biotech. Pharmaceutical manufacturers are reassessing pricing and supplier strategies to balance regulatory requirements, payer expectations, and supply chain resilience.

Methodology & Data Sources

This analysis utilizes a mixed-methods approach, combining primary interviews with industry executives, clinical specialists, and regulatory officials alongside secondary review of scientific publications, agency documents, and market databases. Rigorous triangulation ensures all insights are validated across independent information streams for relevance and accuracy.

Why This Report Matters

Strategic leaders gain actionable recommendations for optimizing manufacturing platforms, supply chain networks, and cross-sector collaborations.
Decision-makers can assess tariff impacts and evolving regulatory requirements to safeguard operational continuity and investment priorities.
Comprehensive segmentation and regional analysis enable tailored market access and resource allocation strategies aligned with current and emerging trends.

Conclusion

Monoclonal antibody therapeutics present opportunities for growth, resilience, and innovation across the biopharmaceutical spectrum. Senior decision-makers can use this analysis to inform strategic direction in a complex and rapidly evolving market landscape.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Market Sizing & Forecasting

5. Market Dynamics

5.1. Rising adoption of bispecific monoclonal antibodies for oncology and immunology applications
5.2. Integration of artificial intelligence in antibody design to accelerate candidate identification
5.3. Surge in development of antibody drug conjugates targeting solid tumor antigens with enhanced potency
5.4. Expansion of subcutaneous monoclonal antibody formulations to improve patient self-administration compliance
5.5. Emergence of biosimilar monoclonal antibodies driving cost competition and market access in oncology
5.6. Advancements in glycoengineering to optimize monoclonal antibody effector functions and reduce immunogenicity
5.7. Growth of immuno-oncology combination therapies pairing monoclonal antibodies with checkpoint inhibitors and CAR T cells
5.8. Increasing use of monoclonal antibodies for treatment of emerging viral infections and global pandemic preparedness
5.9. Implementation of continuous manufacturing processes to streamline monoclonal antibody production at scale
5.10. Adoption of novel delivery platforms such as microneedles and inhalation for targeted monoclonal antibody therapies

6. Market Insights

6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Monoclonal Antibody Therapeutics Market, by Indication

8.1. Introduction
8.2. Autoimmune Disorders
8.2.1. Inflammatory Bowel Disease
8.2.2. Multiple Sclerosis
8.2.3. Psoriasis
8.2.4. Rheumatoid Arthritis
8.3. Cardiovascular Conditions
8.4. Infectious Diseases
8.4.1. COVID-19
8.4.2. HIV
8.4.3. Respiratory Syncytial Virus
8.5. Neurological Disorders
8.5.1. Alzheimer’s Disease
8.5.2. Multiple Sclerosis
8.6. Oncology
8.6.1. Hematological Malignancies
8.6.1.1. Leukemia
8.6.1.2. Multiple Myeloma
8.6.1.3. Non-Hodgkin Lymphoma
8.6.2. Solid Tumors
8.6.2.1. Breast Cancer
8.6.2.2. Colorectal Cancer
8.6.2.3. Lung Cancer

9. Monoclonal Antibody Therapeutics Market, by Antibody Type

9.1. Introduction
9.2. Chimeric
9.3. Fully Human
9.4. Humanized
9.5. Murine

10. Monoclonal Antibody Therapeutics Market, by Molecular Target

10.1. Introduction
10.2. CD20
10.3. EGFR
10.4. HER2
10.5. TNF Alpha

11. Monoclonal Antibody Therapeutics Market, by Production Technology

11.1. Introduction
11.2. Hybridoma
11.3. Recombinant DNA
11.4. Transgenic Animal

12. Monoclonal Antibody Therapeutics Market, by Route Of Administration

12.1. Introduction
12.2. Intramuscular
12.3. Intravenous
12.4. Subcutaneous

13. Monoclonal Antibody Therapeutics Market, by Distribution Channel

13.1. Introduction
13.2. Offline Pharmacy
13.2.1. Hospital Pharmacy
13.2.2. Retail Pharmacy
13.2.3. Specialty Pharmacy
13.3. Online Pharmacy

14. Monoclonal Antibody Therapeutics Market, by End User

14.1. Introduction
14.2. Clinics
14.3. Diagnostic Laboratories
14.4. Hospitals
14.5. Specialty Centers

15. Monoclonal Antibody Therapeutics Market, by Therapy Type

15.1. Introduction
15.2. Combination Therapy
15.3. Monotherapy

16. Americas Monoclonal Antibody Therapeutics Market

16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. Argentina

17. Europe, Middle East & Africa Monoclonal Antibody Therapeutics Market

17.1. Introduction
17.2. United Kingdom
17.3. Germany
17.4. France
17.5. Russia
17.6. Italy
17.7. Spain
17.8. United Arab Emirates
17.9. Saudi Arabia
17.10. South Africa
17.11. Denmark
17.12. Netherlands
17.13. Qatar
17.14. Finland
17.15. Sweden
17.16. Nigeria
17.17. Egypt
17.18. Turkey
17.19. Israel
17.20. Norway
17.21. Poland
17.22. Switzerland

18. Asia-Pacific Monoclonal Antibody Therapeutics Market

18.1. Introduction
18.2. China
18.3. India
18.4. Japan
18.5. Australia
18.6. South Korea
18.7. Indonesia
18.8. Thailand
18.9. Philippines
18.10. Malaysia
18.11. Singapore
18.12. Vietnam
18.13. Taiwan

19. Competitive Landscape

19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. F. Hoffmann-La Roche Ltd
19.3.2. AbbVie Inc.
19.3.3. Merck & Co., Inc.
19.3.4. Bristol-Myers Squibb Company
19.3.5. Johnson & Johnson
19.3.6. Amgen Inc.
19.3.7. Novartis AG
19.3.8. Pfizer Inc.
19.3.9. AstraZeneca PLC
19.3.10. Sanofi S.A.

20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix

List of Figures

FIGURE 1. MONOCLONAL ANTIBODY THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. MONOCLONAL ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 31. MONOCLONAL ANTIBODY THERAPEUTICS MARKET: RESEARCHAI
FIGURE 32. MONOCLONAL ANTIBODY THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 33. MONOCLONAL ANTIBODY THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 34. MONOCLONAL ANTIBODY THERAPEUTICS MARKET: RESEARCHARTICLES

List of Tables

TABLE 1. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR CONDITIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR CONDITIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COVID-19, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COVID-19, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HIV, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ALZHEIMER’S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ALZHEIMER’S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FULLY HUMAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MURINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MURINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CD20, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CD20, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY EGFR, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY EGFR, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HER2, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HER2, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY TNF ALPHA, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY TNF ALPHA, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HYBRIDOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HYBRIDOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RECOMBINANT DNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RECOMBINANT DNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY TRANSGENIC ANIMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY TRANSGENIC ANIMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 197. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 198. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 199. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
TABLE 200. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2030 (USD MILLION)
TABLE 201. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 202. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 203. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 204. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 205. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 206. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 207. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 208. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 209. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 210. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 211. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 212. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 213. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2018-2024 (USD MILLION)
TABLE 214. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2025-2030 (USD MILLION)
TABLE 215. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 216. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 217. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 222. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 223. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 226. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 227. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 228. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 229. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
TABLE 230. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2030 (USD MILLION)
TABLE 231. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 232. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 233. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 234. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 235. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 236. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 237. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 238. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 239. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 240. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 241. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 242. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 243. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2018-2024 (USD MILLION)
TABLE 244. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2025-2030 (USD MILLION)
TABLE 245. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 246. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 247. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 248. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 249. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 252. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 253. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 256. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 257. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 258. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2030 (USD MILLION)
TABLE 261. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 262. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2025-2030 (USD MILLION)
TABLE 275. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 276. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 277. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 278. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 279. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 282. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 283. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 286. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 287. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 288. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 289. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
TABLE 290. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2030 (USD MILLION)
TABLE 291. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 292. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 293. AR

Samples

LOADING...

Companies Mentioned

F. Hoffmann-La Roche Ltd
AbbVie Inc.
Merck & Co., Inc.
Bristol-Myers Squibb Company
Johnson & Johnson
Amgen Inc.
Novartis AG
Pfizer Inc.
AstraZeneca PLC
Sanofi S.A.

Table Information

Report Attribute	Details
No. of Pages	180
Published	August 2025
Forecast Period	2025 - 2030
Estimated Market Value ( USD ) in 2025	$ 189.89 Billion
Forecasted Market Value ( USD ) by 2030	$ 325.76 Billion
Compound Annual Growth Rate	11.4%
Regions Covered	Global
No. of Companies Mentioned	10

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3144EUR$3,545USD£2,727GBP €3494EUR$3,939USD£3,030GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3392EUR$3,824USD£2,942GBP €3769EUR$4,249USD£3,269GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€4597EUR$5,183USD£3,987GBP €5108EUR$5,759USD£4,430GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€5563EUR$6,272USD£4,825GBP €6181EUR$6,969USD£5,361GBP

Market Snapshot: Monoclonal Antibody Therapeutics Market Overview

Scope & Segmentation

Key Takeaways

Tariff Impact: Shifting Cost and Supply Chain Dynamics

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Samples

Companies Mentioned

Table Information

Related Topics

Related Reports

Humanized Monoclonal Antibody Market - Global Forecast 2025-2030

Cancer Monoclonal Antibodies Market - Global Forecast 2025-2030

Biopharmaceutical Market Report by Indication (Autoimmune Diseases, Oncology, Metabolic Disorders, and Others), Class (Recombinant Proteins, Monoclonal Antibodies, Purified Proteins), and Region 2025-2033

Monoclonal Antibodies Market Report and Forecast 2025-2034

Monoclonal Antibody Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F